keyword
MENU ▼
Read by QxMD icon Read
search

Valsartan

keyword
https://www.readbyqxmd.com/read/29341471/the-impact-of-a-dose-of-the-angiotensin-receptor-blocker-valsartan-on-post-myocardial-infarction-ventricular-remodelling
#1
Kyungil Park, Young-Dae Kim, Ki-Sik Kim, Su-Hoon Lee, Tae-Ho Park, Sang-Gon Lee, Byung-Soo Kim, Seung-Ho Hur, Tae-Hyun Yang, Joo-Hyun Oh, Taek-Jong Hong, Jong-Sun Park, Jin-Yong Hwang, Byungcheon Jeong, Woo-Hyung Bae
AIMS: Although clinical guidelines advocate the use of the highest tolerated dose of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after acute myocardial infarction (MI), the optimal dosing or the risk-benefit profile of different doses have not been fully identified. METHODS AND RESULTS: In this multicentre trial, 495 Korean patients with acute ST segment elevation MI and subnormal left ventricular (LV) ejection fraction (<50%) were randomly allocated (2:1) to receive maximal tolerated dose of valsartan (titrated up to 320 mg/day, n = 333) or low-dose valsartan (80 mg/day, n = 162) treatment...
January 17, 2018: ESC Heart Failure
https://www.readbyqxmd.com/read/29338113/efficacy-and-safety-of-sacubitril-valsartan-in-patients-with-essential-hypertension-uncontrolled-by-olmesartan-a-randomized-double-blind-8-week-study
#2
Deanna G Cheung, Diego Aizenberg, Vladimir Gorbunov, Kudsia Hafeez, Chien-Wei Chen, Jack Zhang
A majority of patients with hypertension fail to achieve blood pressure (BP) control despite treatment with commonly prescribed drugs. This randomized, double-blind phase III trial assessed the superiority of sacubitril/valsartan 200 mg (97/103 mg) to continued olmesartan 20 mg in reducing ambulatory systolic BP after 8-week treatment in patients with mild to moderate essential hypertension uncontrolled with olmesartan 20 mg alone. A total of 376 patients were randomized to receive either sacubitril/valsartan (n = 188) or olmesartan (n = 188)...
January 16, 2018: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29338112/benefits-and-pitfalls-of-sacubitril-valsartan-treatment-in-patients-with-hypertension
#3
Steven G Chrysant
No abstract text is available yet for this article.
January 16, 2018: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29337671/spectrophotometric-method-for-simultaneous-determination-of-valsartan-and-substances-from-the-group-of-statins-in-binary-mixtures
#4
Mariusz Stolarczyk, Anna Apola, Anna Maślanka, Anna Kwiecień, Włodzimierz Opoka
Applicability of derivative spectrophotometry for the determination of valsartan in the presence of a substance from the group of statins was checked. The obtained results indicate that the proposed method may be effective by using appropriate derivatives: for valsartan and fluvastatin - D1, D2 and D3, for valsartan and pravastatin - D1 and D3, for valsartan and atorvastatin - D2 and D3. The method was characterized by high sensitivity and accuracy. Linearity was maintained in the following ranges: 9.28-32...
December 20, 2017: Acta Pharmaceutica
https://www.readbyqxmd.com/read/29327807/uric-acid-is-important-but-there-is-something-that-matters-even-more-to-deliver-sacubitril-valsartan-to-eligible-heart-failure-patients
#5
EDITORIAL
Maria Rosa Costanzo
No abstract text is available yet for this article.
January 12, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29325796/lcz696-sacubitril-valsartan-an-angiotensin-receptor-neprilysin-inhibitor-attenuates-cardiac-hypertrophy-fibrosis-and-vasculopathy-in-a-rat-model-of-chronic-kidney-disease
#6
Yasunori Suematsu, Wanghui Jing, Ane Nunes, Moti L Kashyap, Mahyar Khazaeli, Nosratola D Vaziri, Hamid Moradi
BACKGROUND: Chronic kidney disease (CKD) is associated with cardiac hypertrophy, fibrosis and increased risk of cardiovascular mortality. LCZ696 (Sacubitril/valsartan) is a promising agent which has shown significant potential in treatment of heart failure. We hypothesized that LCZ696 is more effective than valsartan alone in treatment of cardiovascular abnormalities associated with experimental CKD. METHODS AND RESULTS: Male Sprague Dawley rats underwent 5/6 nephrectomy and were subsequently randomized to no treatment (CKD), 30 mg/kg valsartan (VAL), or 60 mg/kg LCZ696 (LCZ)...
January 8, 2018: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/29324464/sacubitril-valsartan-associated-small-bowel-ileus
#7
Lilianna Hanefeld-Fox, Lissette Jimenez, Rebecca Heflin, Luis Quiel
No abstract text is available yet for this article.
January 8, 2018: American Journal of Therapeutics
https://www.readbyqxmd.com/read/29318651/effect-of-the-angiotensin-receptor-neprilysin-inhibitor-sacubitril-valsartan-on-pharmacokinetics-and-pharmacodynamics-of-a-single-dose-of-furosemide
#8
Surya Ayalasomayajula, Uwe Schuehly, Parasar Pal, Fabian Chen, Wei Zhou, Gangadhar Sunkara, Thomas H Langenickel
AIMS: Sacubitril/valsartan is indicated for the treatment of heart failure and reduced ejection fraction (HFrEF). Furosemide, a loop diuretic commonly used for the treatment of HFrEF, may be co-administrated with sacubitril/valsartan in clinical practice. The effect of sacubitril/valsartan on pharmacokinetics and pharmacodynamics of furosemide was evaluated in this open label, two- period, single-sequence study in healthy subjects (N=28). METHODS: All subjects received 40 mg oral single dose furosemide during period 1 followed by washout of 2 days...
January 9, 2018: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29316213/comparative-effects-of-valsartan-plus-either-cilnidipine-or-hydrochlorothiazide-on-home-morning-blood-pressure-surge-evaluated-by-information-and-communication-technology-based-nocturnal-home-blood-pressure-monitoring
#9
Takeshi Fujiwara, Naoko Tomitani, Hiroshi Kanegae, Kazuomi Kario
The authors tested the hypothesis that a valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension, defined as systolic BP (SBP) ≥135 mm Hg or diastolic BP ≥85 mm Hg assessed by a self-measuring information and communication technology-based home BP monitoring device more than three times before either combination's administration. This was an 8-week prospective, multicenter, randomized, open-label clinical trial...
January 5, 2018: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29286056/sacubitril-and-valsartan-fixed-combination-to-reduce-heart-failure-events-in-post-acute-myocardial-infarction-patients
#10
M Zaid Iskandar, C C Lang
Heart failure is a term used to define a constellation of symptoms and signs that are commonly attributed to the inability of the heart to produce a cardiac output that meets the demands of the body. It remains a deadly disease, affecting between 1-2% of the population, and is more common in the elderly, with around 6-10% of patients over 65 suffering from the condition. Sacubitril/valsartan (LCZ-696) is a combined neprilysin inhibitor and angiotensin AT1 receptor blocker approved in recent years for the treatment of chronic heart failure with reduced ejection fraction...
October 2017: Drugs of Today
https://www.readbyqxmd.com/read/29276929/-choice-of-angiotensin-receptor-blocker-at-various-stages-of-the-cardiovascular-continuum
#11
V I Podzolkov, N A Dragomiretskaya
We present in this paper modern views on components, physiological and pathophysiological effects of the renin-angiotensin system, pathways of its hyperactivation at various stages of the cardiovascular continuum. Special emphasis is made on angiotensin receptor blockers (sartans). Basing on results of analysis of randomized clinical trials of these agents we have outlined clinical situations in which prescription of one or another drug from this group is preferable. For patients with multiple risk factors of cardiovascular complications preferable agent is telmisartan, for patients with nephropathy - irbesartan, for survivors of acute myocardial infarction - valsartan, while for patients with clinical signs of chronic heart failure with low ejection fraction 3 agents can be designated as preferrable - losartan, valsartan, and candesartan...
October 2017: Kardiologiia
https://www.readbyqxmd.com/read/29262406/sacubitril-valsartan-in-clinical-practice-the-italian-experience
#12
Roberto Valle, Nadia Aspromonte
No abstract text is available yet for this article.
2017: Cardiology
https://www.readbyqxmd.com/read/29262405/management-of-a-multicomorbid-patient-with-heart-failure
#13
Gianluigi Magri, Crescenzio Bentivenga, Eugenio Roberto Cosentino, Daniela Degli Esposti, Claudio Borghi, Ada Dormi
The optimal use of sacubitril/valsartan in clinical practice needs further investigation, in particular for patients with multiple comorbidities, as such patients are usually poorly represented in clinical trials. To this end, well-documented case reports may add further evidence to the bulk of "field practice" experience on sacubitril/valsartan. We report here the case of a patient with heart failure with reduced ejection refraction with multiple comorbidities treated with sacubitril/valsartan. Overall, sacubitril/valsartan led to a prompt (within a few months) improvement in LVEF (+15%, from 38 to 53%), without any noticeable adverse events...
2017: Cardiology
https://www.readbyqxmd.com/read/29262403/sacubitril-valsartan-in-an-elderly-patient-with-heart-failure-a-case-report
#14
Matteo Cameli, Maria Concetta Pastore, Antonio Pagliaro, Cristina Di Tommaso, Rosanna Reccia, Valeria Curci, Giulia Elena Mandoli, Sergio Mondillo
Sacubitril/valsartan has recently been approved for the treatment of heart failure with reduced ejection fraction. Given its recent introduction in the armamentarium for the treatment of heart failure (HF), "field-practice" evidence is required to deepen the clinical management of sacubitril/valsartan therapy. We report a relevant case of an elderly patient who achieved major clinical benefits after only 3 months of sacubitril/valsartan therapy. Importantly, in our assessment, we employed speckle tracking echocardiography (STE), a recent echocardiography technique that is non-Doppler and not angle dependent, which analyzes deformations of heart chambers from standard images and allows a fast, reliable, and reproducible assessment of heart function...
2017: Cardiology
https://www.readbyqxmd.com/read/29262402/sacubitril-valsartan-in-field-practice-patients-with-advanced-heart-failure-a-monocentric-italian-experience
#15
Antonella Vincenzi, Francesca Cesana, Antonio Cirò, Laura Garatti, Felice Achilli
Patients with advanced heart failure (HF) experience a continuous decline in quality of life and have a very poor prognosis. Moreover, due to numerous comorbidities present in these patients, transplantation and left ventricular assist devices are usually impracticable in clinical practice. In this challenging setting, administration of inotropic agents may be the only possible therapy; however, this treatment requires frequent hospitalizations. Our hypothesis is that sacubitril/valsartan, given its marked efficacy and manageability, can be safely used in clinical practice in this setting, potentially reducing hospitalizations and the need for inotropic support...
2017: Cardiology
https://www.readbyqxmd.com/read/29262400/sacubitril-valsartan-effect-on-walking-test-and-physical-capability
#16
Luca Sgorbini, Antonella Rossetti, Alfonso Galati
The 6-min walk test (6MWT) is a simple and inexpensive exercise test to evaluate physical functional capacity that is widely used in heart failure (HF) patients. With the 6MWT, a distance <350 m is associated with increased mortality in patients with HF, and change in walking distance >50 m is considered clinically relevant. To our knowledge, information on improvement in physical functional capacity with sacubitril/valsartan, as assessed by the 6MWT, is still scant. In our daily practice, we apply this test to all patients whenever possible; therefore, we report here the findings observed in a small series of 5 patients with HF with reduced ejection fraction after a 1-month treatment with sacubitril/valsartan at full dose...
2017: Cardiology
https://www.readbyqxmd.com/read/29262399/sacubitril-valsartan-in-clinical-practice-a-report-of-2-cases
#17
Eugenio Cosentino
Following the results of the PARADIGM-HF trial, the European Society of Cardiology (ESC) guidelines recommend sacubitril/valsartan to replace ACE inhibitors in ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite optimal therapy and who fit trial criteria. However, the optimal use of sacubitril/valsartan in clinical practice needs further investigation. We report here the cases of 2 patients with HFrEH successfully treated with sacubitril/valsartan in our daily practice...
2017: Cardiology
https://www.readbyqxmd.com/read/29262397/pharmacological-management-of-a-heart-failure-patient-with-severe-obesity
#18
Gerardo Riccio
Obesity is one of the commonest comorbidities in patients with heart failure, and it is associated with increased mortality risk. However, obese patients are often underrepresented in clinical trials and therefore evidence on their management remains scant. In order to expand knowledge on the management of these patients, anecdotal reports may be considered. In the present case report, we discuss the successful management of an obese patient who received sacubitril/valsartan therapy. This treatment was initiated after a 12-month period of losartan therapy, which did not provide any benefit in terms of heart function...
2017: Cardiology
https://www.readbyqxmd.com/read/29249422/sacubitril-valsartan-and-short-term-changes-in-the-6-minute-walk-test-a-pilot-study
#19
Paola Beltrán, Patricia Palau, Eloy Domínguez, Mercedes Faraudo, Eduardo Núñez, Olga Guri, Anna Mollar, Juan Sanchis, Antoni Bayés-Genís, Julio Núñez
BACKGROUND: Impaired exercise capacity is the most disabling symptom in patients with heart failure with reduced ejection fraction (HFrEF). Despite sacubitril/valsartan showing reduced long-term morbidity and mortality over enalapril in HFrEF, its effects on short-term functional capacity remain uncertain. We sought to evaluate the effects of sacubitril/valsartan on a 30-day six-minute walk test in eligible patients with HFrEF. METHODS AND RESULTS: From November 1, 2016 to February 1, 2017, a total of 58 stable symptomatic patients with HFrEF were eligible for sacubitril/valsartan and underwent 6-MWT before and 30days after initiation of sacubitril/valsartan therapy...
February 1, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29241885/cost-effectiveness-of-the-angiotensin-receptor-neprilysin-inhibitor-sacubitril-valsartan-for-patients-with-chronic-heart-failure-and-reduced-ejection-fraction-in-the-netherlands-a-country-adaptation-analysis-under-the-former-and-current-dutch-pharmacoeconomic
#20
COMPARATIVE STUDY
Isaac Corro Ramos, Matthijs M Versteegh, Rudolf A de Boer, Jolanda M A Koenders, Gerard C M Linssen, Joan G Meeder, Maureen P M H Rutten-van Mölken
OBJECTIVES: To describe the adaptation of a global health economic model to determine whether treatment with the angiotensin receptor neprilysin inhibitor LCZ696 is cost effective compared with the angiotensin-converting enzyme inhibitor enalapril in adult patients with chronic heart failure with reduced left ventricular ejection fraction in the Netherlands; and to explore the effect of performing the cost-effectiveness analyses according to the new pharmacoeconomic Dutch guidelines (updated during the submission process of LCZ696), which require a value-of-information analysis and the inclusion of indirect medical costs of life-years gained...
December 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
16092
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"